Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00599820
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Angioid Streaks
- Choroidal Neovascularization
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal Bevacizumab — DRUG
Study Details
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
Key Dates
- First listed
- Jan 24, 2008
- Start date
- Nov 30, 2005
- Status verified
- May 2024
- Primary completion
- Nov 30, 2005
- Completion
- May 31, 2006
Study Design
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
BCVA
Related Studies
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Scottsdale, Arizona
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Gilbert, Arizona